{"entity":{"id":"eik1004","kind":"drug","name":"EIK1004","aka":["IMP1707"],"tldr":"EIK1004 is an experimental pill being studied to block a DNA-repair enzyme in cancer cells.","summary":"PARP1-selective inhibitor, also called IMP1707. The sponsor describes CNS penetration as a development feature. The linked registry records distinguish recruiting, closed, and discontinued studies; those states do not establish comparative efficacy or approval.","status":"phase-2","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06907043","url":"https://clinicaltrials.gov/study/NCT06907043"},{"label":"Primary EIK1004 clinical abstract","url":"https://doi.org/10.1158/1538-7445.am2026-ct287"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["parp"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06907043"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"modality":"Small-molecule PARP1 inhibitor","mechanism":"PARP1-selective inhibitor, also called IMP1707. The sponsor describes CNS penetration as a development feature.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/eik1004/","neighbours":{"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"trial":[{"id":"nct06907043","kind":"trial","name":"A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.","route":"/trials/nct06907043/"}]}}